A rapid learning decision support system, for personalized radiotherapy.

Cancer results in an increasing burden on European community, and personalising cancer therapy can contribute to the sustainability of our health and care systems. Cancer therapy is increasingly being personalised, and we have witnessed a paradigm shift for the medical treatment of some specific diagnostic groups, like GIST and EGFR-positive lung cancers. Radiotherapy (RT) is an integral part of cancer treatment, and time is ripe for personalising radiotherapy. Achieving level I evidence in increasingly difficult given the numerous diseases and patient parameters discovered. Large randomised trials underlying all changes in guidelines has proven to be ineffective, and new strategies are needed for identifying optimal treatment for patient subpopulations based on patient and disease characteristics.